Key result
Amlodipine/telmisartan single-pill combination provides stable 24-hour blood pressure control, improves the smoothness index, and reduces blood pressure variability in patients with hypertension.
Why the study?
Evaluating effective antihypertensive therapy requires assessing stable 24-hour blood pressure control and variability reduction, raising questions on how to choose optimal first-line single-pill combinations like amlodipine and telmisartan.
Does amlodipine/telmisartan single-pill combination improve 24-hour blood pressure control and smoothness index in patients with arterial hypertension compared to other antihypertensive drugs?
Does amlodipine/telmisartan single-pill combination improve 24-hour blood pressure control and smoothness index in patients with arterial hypertension compared to other antihypertensive drugs?
Amlodipine/telmisartan single-pill combination offers superior 24-hour blood pressure control and improved smoothness index, effectively reducing cardiovascular risk in hypertensive patients.
Answers are grounded in this paper and cite their sources.
May support amlodipine/telmisartan single-pill combination for hypertension; leaves open outcome benefits from reduced variability.
In patients with arterial hypertension (AH), an extremely important measure of the effectiveness of antihypertensive drugs (AHD) is not only a direct decrease in blood pressure (BP), but also its stable control throughout the 24 hours, preventing excessive morning surge and increased BP variability, which in turn are recognized cardiovascular risk factors. Currently, in the vast majority of hypertensive patients, the main antihypertensive therapy approach is using single-pill combinations (SPC) of AHD. Among the first-line combinations for a wide range of patients with AH and no special clinical conditions is amlodipine/telmisartan SPC. Distinctive features of these drugs, on the one hand, are unique pharmacological properties, consisting in an ultra-long antihypertensive effects, superior to other AHD in their classes; and on the other hand, there is an large body of evidence from numerous clinical trials confirming their high antihypertensive and target-organ protective potential as well as excellent capabilities in cardiovascular risk reduction. To assess the AHD effectiveness extent, several parameters have been proposed, of which the most rational and useful is the smoothness index, calculated using the ambulatory blood pressure monitoring data. Smoothness index describes both the degree of BP reduction and its distribution during the monitoring period. This index inversely associates with the changes in BP variability, and has predictive value in relation to the hypertension-mediated organ damage regression during different antihypertensive regimens. Amlodipine/telmisartan SPC has also been studied in many trials, including comparative ones with other AHD. In these works its direct powerful antihypertensive effect and a pronounced beneficial impact on the smoothness index have been proved, demonstrating stable BP control throughout the 24 hours (especially in the most dangerous morning hours), and also a decrease in BP variability. Therefore, amlodipine/telmisartan SPC can effectively reduce cardiovascular risk and improve prognosis in patients with AH.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2020) conducted a review in Arterial hypertension. Amlodipine/telmisartan single-pill combination was evaluated. Amlodipine/telmisartan single-pill combination provides stable 24-hour blood pressure control, improves the smoothness index, and reduces blood pressure variability in patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: